Bradley J. Stish, MD, the lead investigator for the Alliance for Clinical Trials in Oncology trial and a radiation oncologist at the Mayo Clinic (IMAGE)
Caption
“Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer,” said Bradley J. Stish, MD, the Alliance study’s lead investigator and a radiation oncologist at the Mayo Clinic. “These results provide strong support for its use as an effective management option for this challenging and often overlooked side effect of prostate cancer treatment.”
Credit
Mayo Clinic
Usage Restrictions
Mayo Clinic
License
Original content